Phaseline

Companies › TJ Biopharma

TJ Biopharma: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 3 Phase 2, 1 Phase 1, 1 Phase 3; Oncology, Hematology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Plonmarlimab
Granulocyte-macrophage colony-stimulating factor antagonist
CSF2Phase 3Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis; Acute Gouty ArthritisDec 2026
Uliledlimab
CD73 inhibitor
ADORA2APhase 2Non Small Cell Lung CancerAug 2028
TJ037130–Phase 1Solid TumorJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07208058PlonmarlimabPhase 3Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic LymphohistiocytosisHematologyDec 2026
NCT07453004PlonmarlimabPhase 2Acute Gouty ArthritisImmunologyDec 2027
NCT07715747TJ037130Phase 1Solid TumorOncologyJun 2028
NCT06984588UliledlimabPhase 2Non Small Cell Lung CancerOncologyAug 2028
NCT07005336UliledlimabPhase 2Non Small Cell Lung CancerOncologyJan 2029

Targets

ADORA2A (1) CSF2 (1)

Companies with the same targets

Arcus Biosciences Gilead Sciences RDC Clinical Zhejiang Vimgreen Pharmaceuticals iTeos Therapeutics GE Healthcare Innolake Biopharm AstraZeneca BriaCell Therapeutics

Companies built like this

iTeos Therapeutics Innovent Biopharmaceutical Technology (Hangzhou) Nanjing IASO Biotechnology Lepu Biopharma BioRay Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.